Rocket Pharmaceuticals Inc (RCKT)
23.41
+0.62
(+2.72%)
USD |
NASDAQ |
May 03, 15:13
Rocket Pharmaceuticals Research and Development Expense (Quarterly): 41.74M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 41.74M |
| September 30, 2023 | 46.84M |
| June 30, 2023 | 51.38M |
| March 31, 2023 | 46.37M |
| December 31, 2022 | 50.04M |
| September 30, 2022 | 43.38M |
| June 30, 2022 | 41.36M |
| March 31, 2022 | 30.79M |
| December 31, 2021 | 33.02M |
| September 30, 2021 | 39.62M |
| June 30, 2021 | 24.53M |
| March 31, 2021 | 28.31M |
| December 31, 2020 | 50.09M |
| September 30, 2020 | 21.66M |
| June 30, 2020 | 16.73M |
| March 31, 2020 | 16.96M |
| December 31, 2019 | 13.95M |
| September 30, 2019 | 14.83M |
| June 30, 2019 | 13.99M |
| March 31, 2019 | 15.14M |
| December 31, 2018 | 23.68M |
| Date | Value |
|---|---|
| September 30, 2018 | 13.06M |
| June 30, 2018 | 10.77M |
| March 31, 2018 | 5.743M |
| December 31, 2017 | 4.194M |
| September 30, 2017 | 4.894M |
| June 30, 2017 | 2.819M |
| March 31, 2017 | 2.285M |
| December 31, 2016 | 9.493M |
| September 30, 2016 | 8.412M |
| June 30, 2016 | 6.465M |
| March 31, 2016 | 7.615M |
| December 31, 2015 | 5.919M |
| September 30, 2015 | 3.612M |
| June 30, 2015 | 1.954M |
| March 31, 2015 | 1.069M |
| December 31, 2014 | 0.937M |
| September 30, 2014 | 1.243M |
| June 30, 2014 | 1.862M |
| March 31, 2014 | 1.55M |
| December 31, 2013 | 1.592M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
13.95M
Minimum
Dec 2019
51.38M
Maximum
Jun 2023
32.93M
Average
33.02M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| ADMA Biologics Inc | 0.4455M |
| Geron Corp | 32.91M |
| Madrigal Pharmaceuticals Inc | 70.64M |
| Ligand Pharmaceuticals Inc | 5.488M |
| Puma Biotechnology Inc | 12.87M |